A team of scientists from Harvard’s Wyss Institute has created a novel biomaterial that can stimulate T cells to trigger vascularization of ischemic tissues. The researchers demonstrated that their newly designed biomaterial has led to the development of local blood vessels, increased blood transfusion, and growth of new muscles after ischemia.
The team further elaborated the research and tested the operating technique on mice that were suffering from hindlimb ischemia. The researchers first delivered an injection of an egg white protein, ovalbumin. Then they injected a low dosage of aluminum, which stimulated T-helper 2 cells production. After two weeks, they injected a booster vaccine and implanted the pro-vascularizing biomaterial. The implantation further boosted the formation of ovalbumin-specific eosinophils and T-helper 2 cells, as ovalbumin protein was present in the implanted biomaterial. This combination of protein, vaccines, and biomaterial resulted in the development of new blood vessels.
The researchers conducted the trial on lab mice with ischemic tissues and gave the biomaterial-based treatment to a group of the modeled mice. After two weeks, the team observed that there was minor indications of tissue death, more regenerated muscles, and increased blood perfusion in the treated mice.
On a similar note, Nottingham University researchers have created a novel biodegradable material that works as a chemotherapeutic medicine for brain cancer treatment. The researchers performed a laboratory trial in which they applied the paste of biodegradable material on the brain tissues of rats. They observed that the survival rate of those rats was boosted as against controls. This groundbreaking innovation may one day emerge effective and more reliable treatment options for the people suffering from cancers, particularly glioblastoma.
Actually, the biodegradable material was in a particulate or powder form, but the researchers added water to change its state into gel or paste. The gel contains two chemotherapeutic drugs: etoposide and temozolomide, which liberate slowly with the gel degradation and kills the residual tumorous cells.